Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease

Next Previous
X
Search
Trial Profile

Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Anastrozole; Antineoplastics; Exemestane; Letrozole; Tamoxifen
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms PACS11UNIRAD; UCBG-UNIRAD; UNIRAD

    • Most Recent Events

    • 06 Jun 2023 Results (n=855) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 23 May 2022 Status changed from active, no longer recruiting to discontinued, according to Results published in the Journal of Clinical Oncology.
    • 23 May 2022 Primary endpoint (To evaluate the benefit from adding everolimus to standard endocrine treatments after two years of treatment on the disease-free survival (DFS)) has not been met, according to Results published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top